Effect of the HCC-EduLink Intervention

L
Lauren Nephew

Primary Investigator

Enrolling By Invitation
18 years - 100 years
All
Phase N/A
40 participants needed
1 Location

Brief description of study

The objective of this study is to pilot test a multi-level intervention designed to address patient- and system-level social and structural determinants of health (SSDOH) variables and facilitate access to curative hepatocellular carcinoma (HCC) therapies, including liver transplantation and resection, in a cohort of Black patients with Barcelona Clinic Liver Cancer prognosis stage 0, A and downstaged B disease. The main aim of this study is to estimate the effect of the HCC-EduLink intervention on the time to receipt of curative therapies and HCC related knowledge in Black patients with HCC.

THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic. 
 
Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:
IU Clinical Trials Office 
Phone: (317) 278-5632

Detailed description of study

Individuals will be randomized 1:1 to either HCC-EduLink + SOC or SOC alone. 

SOC is care provided by hepatologist, oncologist, interventional radiologist, and/or surgeon. 

Patients will be followed for 8 months because our median time from LT evaluation start to LT wait listing in patients with HCC is 155 days in Black patients and 122 days in White patients (center-specific data).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Barcelona Clinic Liver Cancer
  • Age: 18 years - 100 years
  • Gender: All

Inclusion criteria
  • Diagnosed with BCLC stage 0, A or downstaged B HCC
Exclusion criteria
  • BCLC B disease that is unable to be downstaged
  • BCLC C and D disease
  • Currently waitlisted for LT
  • Post-transplant of any solid organ

Updated on 29 Jul 2025. Study ID: GI-NIMHD-HCC-EDULINK, 23696
Please visit our main page to search for other studies you may be interested in. If you need help finding a study or have any questions, please contact us at inhealth@iu.edu

Interested in the study?

This study is accepting only persons who receive care at a certain clinic or doctor or who are part of an invited group. Questions about this study can be directed to the study team listed in the description or contact your doctor to see if you are eligible.

Accepting Referrals by Invitation Only